Skye Bioscience, Inc.: Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
Skye Bioscience (Nasdaq: SKYE) will acquire privately held Redx Pharma via a UK scheme of arrangement, forming Fibrx Therapeutics that will trade on Nasdaq. The deal includes about $125 million in committed financings, including a ~$68 million PIPE and a $36 million Series A. Funds are expected to support RXC008 Phase 2 through 2029, with topline data in H2 2028.
How this was made
The 30-second read
Why it matters
The transaction combines a financing package (~$125M gross) with a clinical roadmap centered on RXC008 Phase 2 topline expected in H2 2028, funded through 2029.
Market read
Definitive M&A plus a committed multi-tranche financing is a direct catalyst for SKYE and sets expectations for funding runway and the next clinical inflection point.
What to watch
Key deal terms are not fully detailed here (valuation, PIPE pricing, warrant strike, and closing conditions), so traders may need to wait for definitive documentation and shareholder vote timing.
Background
Skye (Nasdaq: SKYE) and privately-held Redx (U.K.) announced a definitive acquisition of Redx, with the combined company to operate as Fibrx Therapeutics on Nasdaq.
Ticker impact
Skye will acquire Redx via a U.K. scheme of arrangement and fund the combined company with about $125M gross proceeds, including a PIPE and equity line.
Likely positive near-term on deal certainty and funding size, but volatility around PIPE terms and Q4 2026 closing risk.
The article discloses a definitive transaction agreement, Nasdaq listing plan under Fibrx, and committed financing components totaling ~$125M, which are direct drivers of SKYE’s capital structure and risk profile.
Market effects
Highlights continued investor appetite for fibrosis and GI-IBD anti-fibrotic small molecules, potentially supporting sentiment for similar preclinical/Phase 2 programs.
Nasdaq listing plan for the combined entity may shift attention and liquidity toward U.S.-listed fibrosis biotech peers.
U.K. scheme of arrangement and U.S. FDA Fast Track context underscore cross-border capital flows into U.S.-centric clinical development.
Counterpoint
The $125M headline may not fully de-risk RXC008’s Phase 2 outcome, and the equity line plus PIPE can increase dilution and overhang into the trial.
Key entities
- public_companySkye Bioscience, Inc.
Nasdaq-listed acquirer planning to acquire Redx and operate the combined entity as Fibrx on Nasdaq.
- private_companyRedx Pharma Limited
U.K. clinical-stage biotech whose lead asset RXC008 will drive the combined company’s Phase 2 program.
- combined_companyFibrx Therapeutics, Inc.
Planned Nasdaq-traded operating name for the combined Skye-Redx entity.
- lead_programRXC008
GI-restricted pan-ROCK inhibitor for fibrostenotic Crohn’s disease, with Phase 2 topline expected in H2 2028.
